- European markets gain slightly during Tuesday's session
- Fresenius Medical publishes quarterly results
- Bayer cuts its dividend by 95%
Overall market situation
Tuesday's session on European stock markets brings mixed investor sentiment. Most of the Old Continent's indices are up today, but their scale is not overly large. In this respect, the Polish WIG20 stands out above all today, which is currently the growth leader in the region. Investors' attention is today focused on the results of Fresenius Medical and the Bayer dividend decision.
Start investing today or test a free demo
Create account Try a demo Download mobile app Download mobile app
European companies listed during Tuesday's trading session are currently trading at mixed levels. Source: xStation 5
The German benchmark DE40 remains within the constraints set by the 17,100-point barrier during Tuesday's session. From a technical point of view, further increases and a possible breakout above the 17,150-point zone could encourage the buyers' side to retest the recent local maxima of 16 February. The most important zone of possible support could now be the local low marked by the 50-day exponential moving average (blue curve on the chart). Source: xStation 5
News:
Shares of Fresenius Medical (FME.DE) are losing nearly 1% during today's session following the release of quarterly results. Analysts at Citi commented that Q4 results were "largely quiet", while forecasts for 2024 are also in line with expectations.
FOURTH QUARTER RESULTS
- Operating income EU428 million, +22% y/y, estimate EU381.7 million (Bloomberg Consensus)
- Revenue EU4.99 billion, -0.2% y/y, estimate EU4.97 billion
- Operating income excluding special items EU555 million, +13% q/q, estimate EU467.4 million
- Net income EU188 million, estimate EU177.2 million
- Net income excluding special items EU259 million, estimate EU230 million
- Basic EPS EU0.64, estimate EU0.57
- Basic earnings per share excluding special items EU0.88, estimate EU0.82
2023 YEAR RESULTS
Dividend per share EU1.19, estimate EU1.02
COMMENTARY AND CONTEXT
- Expects operating income to grow by a mid- to high-teens percent rate compared to prior year
- The 2023 basis for the revenue outlook is €19.05 billion and for the operating income outlook is €1.54 billion, both numbers are adjusted for the positive impact of the Tricare settlement and the operating business impact from divestments closed by year-end 2023
- The company reaffirms its targets to achieve an operating income margin of 10% to 14% by 2025. This excludes impacts from portfolio changes
Source: xStation 5
Bayer (BAYN.DE) shares are gaining 1% today after the German agri-pharmaceutical conglomerate announced it would cut its dividend by 95% after an avalanche of bad news halved its market capitalisation over the past year. A spoiling factor for sentiment around the company is the continuing lawsuits over the use of Roundup. As reported by Morgan Stanley, the move will support the company's budget by nearly €5.2 billion.
Analyst recommendations:
Bernstein reiterated a 'buy' rating on shares of Siemens Healthineers (SHL.DE). Target price of €66.5 per share.
The content of this report has been created by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, (KRS number 0000217580) and supervised by Polish Supervision Authority ( No. DDM-M-4021-57-1/2005). This material is a marketing communication within the meaning of Art. 24 (3) of Directive 2014/65/EU of the European Parliament and of the Council of 15 May 2014 on markets in financial instruments and amending Directive 2002/92/EC and Directive 2011/61/EU (MiFID II). Marketing communication is not an investment recommendation or information recommending or suggesting an investment strategy within the meaning of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC and Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest or any other advice, including in the area of investment advisory, within the meaning of the Trading in Financial Instruments Act of 29 July 2005 (i.e. Journal of Laws 2019, item 875, as amended). The marketing communication is prepared with the highest diligence, objectivity, presents the facts known to the author on the date of preparation and is devoid of any evaluation elements. The marketing communication is prepared without considering the client’s needs, his individual financial situation and does not present any investment strategy in any way. The marketing communication does not constitute an offer of sale, offering, subscription, invitation to purchase, advertisement or promotion of any financial instruments. XTB S.A. is not liable for any client’s actions or omissions, in particular for the acquisition or disposal of financial instruments, undertaken on the basis of the information contained in this marketing communication. In the event that the marketing communication contains any information about any results regarding the financial instruments indicated therein, these do not constitute any guarantee or forecast regarding the future results.
